Bank of America Securities: Maintains the "Buy" rating for SINO BIOPHARM, with the Target Price raised to 181 Hong Kong dollars.
Bank of America Securities released a research report stating that based on SINO BIOPHARM's (01177) latest Company Business Data, the revenue forecasts for 2024 to 2026 have been slightly adjusted upward by 0.1%, 0.2%, and 0.2%, to 29.052 billion, 31.816 billion, and 34.722 billion yuan respectively. This year's earnings per share forecast has also been raised from 0.11 yuan to 0.20 yuan. Considering its strong sales performance and good progress in product pipeline development, Bank of America has raised the Target Price for SINO BIOPHARM from 3.8 HKD to 4 HKD, reiterating a 'Buy' rating.
Overwhelming consensus! Wall Street "targets" Banks stocks as the top choice for 2025.
Buying bank stocks has become the overwhelming consensus among strategists at major Wall Street firms regarding their outlook for 2025.
SA Asks: How Should Investors Position Portfolios Ahead of Fed Vote?
Why Wall Street Says Bank Stocks Are a Top Play for 2025
BofA, Goldman Sachs To Contribute To Trump's Inaugural Committees: Report
Bank of America Options Spot-On: On December 13th, 149.75K Contracts Were Traded, With 3.37 Million Open Interest
Mercado : Here comes the![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Dragon kuku bird ❤ :